Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme

J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e590-e592. doi: 10.1111/jdv.18082. Epub 2022 Mar 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Humans
  • Skin Neoplasms* / drug therapy
  • United Kingdom

Substances

  • Antibodies, Monoclonal, Humanized
  • cemiplimab